ArticleResearch in pharmaceutical sciences2020
Evaluation of neuroprotective effects of alpha-tocopherol in cuprizone-induced demyelination model of multiple sclerosis.
Article in Research in pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- mPFC hemorrhage induces hippocampal CA1 dendritic spine plasticity and attentional deficits in mice.Research in pharmaceutical sciences · 2026Article
- Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms.Molecular neurobiology · 2026Article
- The role of α-tocopherol in the prevention and treatment of Alzheimer's disease.Molecular and cellular biochemistry · 2025Review
- Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Identification of Six Cerebrospinal Fluid Metabolites Causally Associated with Anorexia Nervosa Risk: A Mendelian Randomization Analysis.International journal of molecular sciences · 2025Article
- Marginal Zinc Deficiency during Gestation and Lactation in Rats Affects Oligodendrogenesis, Motor Performance, and Behavior in the Offspring.The Journal of nutrition · 2023Article
- Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies.Brain : a journal of neurology · 2023Article
- Design and synthesis of some novel triazine-tyrosine hybrids as potential agents for the treatment of multiple sclerosis.Research in pharmaceutical sciences · 2022Article
- Locomotor and histological changes in a cuprizone-induced animal model of multiple sclerosis: comparison between alpha-tocopherol and fingolimod.Research in pharmaceutical sciences · 2022Article
- Effects of intrathecal and intracerebroventricular microinjection of kaempferol on pain: possible mechanisms of action.Research in pharmaceutical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeMultiple sclerosis (MS) is an autoimmune disorder characterized by demyelination and axonal loss. Quantitative estimation of behavioral, locomotor, and histological changes following the use of alpha-tocopherol (AT) in the animal model of MS have not been reported. The present study was planned to evaluate whether AT can improve sensorimotor dysfunction and reduce demyelination in the cuprizone (CPZ)-induced rat model of MS. EXPERIMENTAL APPROACH: Female FINDINGS/
resultsDuring withdrawal of CPZ, AT treatment increased the average speed by 22% in group E1, compared to group E2 ( CONCLUSION AND IMPLICATIONS: Short-term AT therapy showed improvement in motor dysfunction and reduction of demyelination in the animal model of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.